



### Enpr-EMA Annual Report 2021-2022

Pirkko Lepola, Chair, Enpr-EMA

# Governance & Queries & Challenges





Meetings (Virtual)

03-March 22 (CG+Networks), 30-June 22 (CG), 04-October 22 (CG+Networks)



CG Members & Networks

Members of Coordinating Group: No changes since 07-2021



Networks status 09-2022;

- **NETSTAP** (Germany): upgraded to <u>category 1</u>.
- PolPedNet (Poland): A new application for national network <u>Under assessment</u>
- **HELPNET** (Greece): A new application for national network <u>Under assessment</u>
- **ECAPN** (Spain): A revised application for national network <u>Under assessment</u>
- PEDSTART (France): A revised application for national network <u>Under assessment</u>
- Japanese network / NCCHD: A revised application for national network <u>Under assessment</u>
- Neocirculation: closed.



Queries from Industry & PDCO

- 1. Paediatric product development for fibrodysplasia ossificans progressiva (FOP) November 2021
- 2. Paediatric product development for Spinocerebellar Ataxia (SCA) and a feasibility study to understand the viability of recruiting and conducting a clinical trial in paediatric patients with SCA December 2021
- 3. Pediatric product development for heart failure March 2022
- 4. 2 queries from the PDCO regarding general questions related to paediatric unmet needs, and feasibility of studies.









4 main challenges;

COVID-19, Ukraine war, "Only Virtual Life", several ongoing initiatives (overlapping human resources)



## Enpr-EMA Secretariat information sharing





#### **Regulatory News**



#### Conferences



Workshops



Initiatives



Webinars



Hearings



Trainings



#### **Reports**



Plans

- 1. Workshop with the title "Advancing the Development of Pediatric Therapeutics (ADEPT 7) 1st, 2nd of September
- MRCT Webinar: Advancing International Pediatric Clinical Research. Part 1: INFORMING THE FUTURE FROM COVID-19 LESSONS LEARNED – 6 & 7 October 2021
- 3. Training modules regarding CTR and CTIS 14 December 2021 (as part of Enpr-EMA newsletter)
- 4. TREAT-NMD DMD Early Diagnosis Training Seminar Spring 2022
- 5. Invitation to take part in beta-testing of a decision tree for inclusion of adolescents in adult trials, which has been developed by the European Forum for Good Clinical Practice (EFGCP) Children's Medicines Working Party (CMWP) December 2021
- 6. Invitation to a virtual event on 'Research in regulatory science addressing the needs' 18 January 2022
- 7. MRCT Webinar: Advancing International Pediatric Clinical Research. Part 2: Time to Listen: Hearing from Young People in Clinical Research 2 February 2022
- 8. Go live of the Clinical Trials Information System (CTIS) 31 January 2022
- 9. Information shared on the c4c external course catalogue 02 February 2022
- 10. The European Commission Directorate General for Health and Food Safety conference on "Health Technology Assessment What's next" 22nd June 2022.
- 11. MRCT Webinar: Advancing International Pediatric Clinical Research. Part 3: Assent and consent in the field: culture, context, and respect. 28-29 June 2022
- 12. TEDDY Hearing within the Council of Europe (COE) regarding children participation in the decision making in the biomedical field 7th of July 2022
- 13. EMA's Annual Report 2021 together with the accompanying message from the EMA's Executive Director shared on July 2022.
- 14. The 2022-2026 workplan of the Accelerate Clinical Trials in the EU (ACT EU) initiative shared on 30 August 2022.
- 15. EFGCP & DIA Better Medicines for Children virtual Conference, October 18-19, 2021
- 16. EFGCP Better Medicines for Children, October 18-19, 2022, and Pre-conference workshop, on the 17th of October focusing on the Fundamentals about Paediatric Extrapolation. (AOB in this meeting)
- 17. MICYRN and CHEER webinar entitled "Research Ethics Review Streamlining Initiatives" 29th of November 2021
- 18. International collaboration between stakeholders for promoting paediatric drug development at the PMDA-ATC & U.S. FDA Pediatric Review Webinar, September 2021
- 19. Congress of the European Society for Developmental, Perinatal, and Paediatric Pharmacology 27th to 30th June 2022
- 20. Enpr-EMA-c4c Worksop on Site Standards / Quality Criteria on October 3, 2022

### **Achievements & Activities**



_

#### Working Group's **Deliverables**

1. Publication: Article "Informed consent and assent guide for paediatric clinical trials in Europe" in Archives of Disease in Childhood - December 2021



#### **Public** consultations

- 1. EU Commission: EU Pharma Strategy Public Consultation- from 28 September 2021 to 21 December 2021
- 2. EU Commission: Unauthorised medicinal products used in clinical trials (labelling rules)" 02 June 2022
  - 3. The International Society for Health Technology Assessment (HTAi), the European Patients Forum (EPF) and the European Patients' Academy on Therapeutic Innovation (EUPATI) survey among HTA stakeholders as part of their research into patient involvement in HTA interactions - 2 June 2022

4. ACCELERATE and the ALADDIN consortium survey regarding a new educational program on strategic and regulatory science in paediatric oncology drug development to foster expertise and strengthen true multi-stakeholder

- collaboration September 2022 5. Survey developed at Radboud University Medical Centre in the Netherlands, that will inform the design of an evidence-based pregnancy formulary as part of project MADAM (Model Adjusted Doses for All Mothers) – September 2022.
- 6. ICH GCP: Consultation on GCP principles (2022) –(AOB in this meeting)



### **WG International**

2 Publications in writing process for CTA + EC 1 Survey to Industry partners completed 1 workshop organized with c4c



**WG Research Nurses** 

Continues -> re-started. European Survey for Research Nurses planned.



WG Patient's Rights

*New plans – article in writing process* 




**WG Labelling - Evidence** P.Lepola

New WG for supporting P&P awareness, Patient's Rights and Cross-border access to CTs

## Enpr-EMA member networks 2022









Category 1 networks are part of the operational centre of Enpr-EMA – **Coordinating Group,** sharing responsibility for the network's longand short-term strategy.

Category 2: Not currently fulfilling all minimum requirements

Category 3: Do not run paediatric clinical trials but have other expertise





# Member networks by therapeutic area and expertise 2022

	multispecialty national	multi- specialty / multi- national	Oncology / Haematolo gy/ Malignanci es	Allergology / immune- logy / Rheumatol ogy	Infectious diseases / Vaccinolog y	Respiratory / Cystic Fibrosis	Neonato logy	Stem Cell / Organ Transplant. / Haematolog Y	Psychiatry / Neurology	Intensive Care / Pain / Anaesthe siology / Surgery	Cardio- logy	Gastro- entero- logy / Hepatol ogy	Diabetes / Endocrinol ogy /metabolic Disorders	Gynaeco logy / Fertility	Special Expertise for CTs	Specialized other Activity
1	OKIDS	c4c	ITCC	PRINTO	PENTA-ID	ECFS-CTN	GNN	EBMT PDWP	EUNETHYDI S	ESPNIC	AEPC Task Force	PEDDCr eN	-	-	TEDDY	FP-MCRN
2	PCIC-Belgium		Newcastle- CLLG	JSWG of PRES	UKPVG	SPACE	INFANT	EPLTN	ECAPN						EAPRASne t	eYPAGnet
3	FINPEDMED		I-BFM-SG	MIWG-JIA	RESVInet	RESVinet									TREAT- NMD	
4	PEDMED-NL		EORCT-CLG	PIBDnet	RITIP										ESPDDD	
5	MRCN-		CEPOETA													
	Hungary															
6	HUNPEDNET															
7	SWISSPEDNE															
	Т															
8	PEDSTART															
9	STAND4KIDS															
10	REDSAMID															
11	NORPEDMED															
12	SCOTCRN															
13	RIPPS															
14	IPCRN-NCRC															
15	NETSTAP															
16	RECLIP															
17	NIHR-CRN															
18	DCRI															
19	MICYRN															
20	NCCHD-Japan															

### Enpr-EMA 2.0



Meaning / benefit of double- or triple...multispecialty memberships and by different criteria for networks and other stakeholders (e.g. sponsors)? Example of C4C

